Skip to main content

Table 4 Clinical data for ankylosing spondylitis patients in stratified by fecal calprotectin positivity

From: Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study

  Fecal calprotectin cutoff 50 μg/g
  Fecal calprotectin positive (n= 16) Fecal calprotectin negative (n= 23) Pvalue
NSAID use 6 (38%) 10 (43%) 0.75
Enbrel use 9 (56%) 8 (35%) 0.20
Patients waking up at night for bowel movement 3 (19%) 3 (13%) 0.67
BASDAI score 3.0 (0.1 to 7.75) 1.8 (0.03 to 7.66) 0.16
BASRI score 6.0 (2 to 13.5) 5.0 (2 to 11) 0.64
BASFI score 41.6 (0.4 to 92.5) 17.1 (0 to 72.1) 0.09
Erythrocyte sedimentation rate 8.5 (0 to 62) 17 (2 to 64) 0.75
C-reactive protein 0.44 (0.03 to 5.7) 0.57 (0.02 to 4.84) 0.58
Patients with history of uveitis 7 (44%) 10 (43%) 1.0
Patients with history of peripheral arthritis in the knee 4 (25%) 5 (22%) 1.0
Patients with history of peripheral arthritis in the ankle 5 (31%) 4 (17%) 0.44
  1. Data presented as median (range) or number (percentage). BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASRI, Bath ankylosing spondylitis radiology index.